We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+0.8%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.76B
AUM Growth
-$301M
Cap. Flow
-$879M
Cap. Flow %
-18.47%
Top 10 Hldgs %
31.51%
Holding
169
New
40
Increased
23
Reduced
18
Closed
45

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$128M
2
BSX icon
Boston Scientific
BSX
+$108M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$89.6M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$76M
5
TOI icon
The Oncology Institute
TOI
+$53.3M

Top Sells

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$87.3M
2
SWTX
SpringWorks Therapeutics
SWTX
+$69.3M
3
OSH
Oak Street Health, Inc.
OSH
+$58.2M
4
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
+$56.1M
5
DFHTU
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
+$50.4M

Sector Composition

Rank Sector Weight
1 Healthcare 70.89%
2 Consumer Discretionary 0.23%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$389M
$12.3M 0.26%
+2,142,857
New +$15.9M
SGFY
77
DELISTED
Signify Health, Inc.
SGFY
$11.7M 0.25%
+400,000
New +$12.4M
BOLT icon
78
Bolt Biotherapeutics
BOLT
$7.64M
$11.5M 0.24%
+17,500
New +$11.4M
STIM icon
79
Neuronetics
STIM
$126M
$11.4M 0.24%
919,000
– –
WOOF icon
80
Petco
WOOF
$777M
$11.1M 0.23%
+500,000
New +$11.9M
SRSAU
81
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$10.8M 0.23%
1,000,000
– –
KNTE
82
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$10.8M 0.23%
345,000
– –
DYN icon
83
Dyne Therapeutics
DYN
$4.24B
$10.7M 0.22%
686,000
+116,000
+20% +$2.24M
BCAB icon
84
BioAtla
BCAB
$5.64M
$10.4M 0.22%
4,108
-1,500
-27% -$3.84M
REVHU
85
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Units
REVHU
$10.1M 0.21%
+1,000,000
New +$10M
MTACU
86
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$10.1M 0.21%
1,000,000
– –
EUCRU
87
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$10M 0.21%
1,000,000
– –
SNRHU
88
DELISTED
Senior Connect Acquisition Corp. I Unit
SNRHU
$10M 0.21%
1,000,000
– –
RNAM
89
DELISTED
Avidity Biosciences
RNAM
$9.9M 0.21%
453,973
– –
OLMA icon
90
Olema Pharmaceuticals
OLMA
$1.05B
$9M 0.19%
271,191
-425,000
-61% -$18.2M
AERI
91
DELISTED
Aerie Pharmaceuticals
AERI
$8.83M 0.19%
494,216
-667,817
-57% -$11.5M
COGT icon
92
Cogent Biosciences
COGT
$6.91B
$8.78M 0.18%
1,000,000
– –
TPTX
93
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.93M 0.17%
83,846
– –
INNV icon
94
InnovAge Holding
INNV
$1.56B
$7.74M 0.16%
+300,000
New +$7.39M
CMIIU
95
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
$7.68M 0.16%
+600,000
New +$7.53M
TMPMU
96
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$7.5M 0.16%
750,000
– –
IMCR icon
97
Immunocore
IMCR
$1.72B
$7.32M 0.15%
+171,908
New +$7.65M
IGNYU
98
DELISTED
Ignyte Acquisition Corp. Unit
IGNYU
$7.26M 0.15%
+725,000
New +$7.5M
FDMT icon
99
4D Molecular Therapeutics
FDMT
$543M
$6.51M 0.14%
150,000
– –
DCTH icon
100
Delcath Systems
DCTH
$412M
$6.21M 0.13%
500,000
– –
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2021 Portfolio in Review

As of Q1 2021, Deerfield Management held 169 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $879M in Q1 2021, closing 45 positions and reducing 18 holdings. Its most notable exit was Nkarta, an estimated $87.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Deerfield Management opened a new position in Edgewise Therapeutics worth $128M.

  • Deerfield Management's largest Q1 2021 buy was Edgewise Therapeutics: 3,933,137 shares worth $128M.
  • Deerfield Management added most to The Oncology Institute in Q1 2021, an estimated $53.3M increase.
  • Deerfield Management's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $69.3M.
  • Deerfield Management fully exited Nkarta in Q1 2021, selling an estimated $87.3M.
  • Deerfield Management's ten largest holdings make up 32% of its $4.76B portfolio in Q1 2021.
  • Deerfield Management opened 40 new positions and closed 45 in Q1 2021.
  • Deerfield Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Deerfield Management's 13F filing for Q1 2021, filed 17 May 2021.